Please ensure Javascript is enabled for purposes of website accessibility

There's a New 15-Minute Coronavirus Test

By Cory Renauer - Updated Apr 1, 2020 at 12:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Becton Dickinson and BioMedomics are the latest companies to launch a quick point-of-care SARS-CoV-2 diagnostic.

A new coronavirus test from Becton Dickinson (BDX 0.54%) can deliver results about 15 minutes after a healthcare provider drops a person's blood sample in the test kit. The new test was developed by BioMedomics, a privately held company based in North Carolina that will also manufacture the point-of-care diagnostic. 

Unlike a recently approved point-of-care test from Abbott (ABT 0.27%) that looks for genetic material specific to SARS-CoV-2, Becton Dickinson's new test looks for some of the proteins produced from that genetic material. On Sunday, the FDA authorized the use of a rapid test that runs on Abbott's toaster-sized nucleic acid amplification machines, which are already in use by healthcare providers across the U.S.

COVID-19 test sample

Image source: Getty Images.

Becton Dickinson's new antibody test hasn't been reviewed by the FDA, but the company will be allowed to distribute it immediately to U.S. healthcare providers thanks to emergency guidance issued by the regulator in March. However, that guidance also makes it clear that results from antibody tests -- whether performed at an urgent care center or a giant laboratory -- should not be used as the sole basis to diagnose a patient or inform them of their infection status.

Becton Dickinson's more widely known for marketing infusion systems than diagnostic tests. Sales of the company's popular Alaris systems, which are used by a majority of healthcare providers in the U.S., are under pressure at the moment. And investors hoping that this new COVID-19 test will offset the decreasing revenue from the infusion system line could be disappointed.

Healthcare providers can order the new coronavirus antibody test from Becton Dickinson, although a company with more experience in the point-of-care diagnostics field, Henry Schein will distribute the test exclusively.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Becton, Dickinson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
BDX
$260.79 (0.54%) $1.39
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$110.79 (0.27%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.